Recurrent Melanoma Completed Phase 2 Trials for Temozolomide (DB00853)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01328535Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryTreatment
NCT00072163Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to MelanomaTreatment